Investigation of cholinergic inhibition by donepezil-rimegepant hybrids in alzheimer’s disease: An in silico study

Simple item page
dc.contributor.authorAsokan, Karthikeyanen_US
dc.contributor.authorParanthaman, Selvarenganen_US
dc.date.accessioned2025-05-09T07:26:26Z
dc.date.available2025-05-09T07:26:26Z
dc.date.issued2024-12
dc.description.abstractAlzheimer's disease (AD) is a neurodegenerative disorder that causes damage to brain cells, resulting in memory loss, thinking, and executive skills. AD is widely recognized as a most prevalent type of dementia that occurs in elder people. Although few medications like donepezil are available to treat AD, a new and effective drug is the need of the hour. Hence, in the present study, an in silico approach is used to investigate the cholinergic inhibition by donepezil-rimegepant hybrids. Inspired by the structure of donepezil and rimegepant, Donepezil-Rimegepant (DR) hybrids are generated using a hybridization-based design strategy. Their biological activity towards acetylcholinesterase, (AChE) butyrylcholinesterase (BuChE) and amyloid ? (A?) peptides is investigated using computational techniques such as DFT and molecular docking. Our DFT calculations indicate that the DR13 is highly stable than the other hybrids considered in this study. Similarly, our molecular docking study revealed that DR13 has strong interactions with AChE, BuChE, and A? peptide. While considering donepezil and the rimegepant region in DR hybrid, later has strong binding with the protein targets considered in this study. This is due to the presence of two F atoms in the benzyl region of rimegepant. These halogens form strong noncovalent interactions with the amino acid residues in the protein targets. Therefore, based on our in silico studies DR13 is proposed as a good candidate molecule for designing a new drug against AD.en_US
dc.identifier.affiliationsDepartment of Physics and International Research Centre, Kalasalingam Academy of Research and Education (Deemed to be University), Krishnankoil-626 126, Tamil Nadu, Indiaen_US
dc.identifier.affiliationsDepartment of Physics and International Research Centre, Kalasalingam Academy of Research and Education (Deemed to be University), Krishnankoil-626 126, Tamil Nadu, Indiaen_US
dc.identifier.citationAsokan Karthikeyan, Paranthaman Selvarengan . Investigation of cholinergic inhibition by donepezil-rimegepant hybrids in alzheimer’s disease: An in silico study . Indian Journal of Biochemistry & Biophysics. 2024 Dec; 61(12): 788-803en_US
dc.identifier.issn0301-1208
dc.identifier.issn0975-0959
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/243262
dc.languageenen_US
dc.publisherCSIR-National Institute of Science Communication and Policy Research (NIScPR)en_US
dc.relation.issuenumber12en_US
dc.relation.volume61en_US
dc.source.urihttps://doi.org/10.56042/ijbb.v61i12.11431en_US
dc.subjectAChEen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectDensity functional theoryen_US
dc.subjectDonepezilen_US
dc.subjectMolecular dockingen_US
dc.subjectRimegepanten_US
dc.titleInvestigation of cholinergic inhibition by donepezil-rimegepant hybrids in alzheimer’s disease: An in silico studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijbb2024v61n12p788.pdf
Size:
4.6 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Biochemistry & Biophysics